Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 53.50 |
---|---|
High | 53.50 |
Low | 53.50 |
Bid | 56.50 |
Offer | 57.00 |
Previous close | 53.50 |
Average volume | 4.00 |
---|---|
Shares outstanding | 49.36m |
Free float | 48.90m |
P/E (TTM) | 733.07 |
Market cap | 2.80bn USD |
EPS (TTM) | 0.0774 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:08 GMT.
More ▼
- Vericel Reports Third Quarter 2024 Financial Results
- Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
- Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
- Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
- Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
- Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
- Vericel Reports Second Quarter 2024 Financial Results
- Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
- Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
- Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
More ▼